Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
-Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that the FDA has granted B...